Development and in silico validation of an online adaptive workflow for proton therapy with an in-room synchrocyclotron and CT-on-rails.
other
Where this comes from
- Record sourced from PubMed, PMID 42526650.
- Also identified by DOI 10.1016/j.ijrobp.2026.07.032.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Development and validation of an online adaptive proton therapy workflow for clinical use. A script-based online adaptive proton therapy workflow was developed in a graphics processing unit (GPU)-accelerated treatment planning system (TPS) to automate plan adaptation using traditional CT images acquired on an in-room CT-on-rails. Monte Carlo (MC) -based secondary dose calculation and log file analysis of machine parameters were integrated into the workflow to provide quality assurance (QA) pre- and post- plan delivery for the adapted treatment plan. In silico retrospective testing was performed with ten previously treated pelvic patients for validation of the workflow, a total of 50 fractions were included in this study. The fidelity of adapted dose distributions, time required for the in-silico workflow, and QA results were recorded and analyzed. The median (inter-quartile range, IQR) time required for this workflow was 61.9 (12.2) minutes, demonstrating technical feasibility for online adaptation. Of the 50 evaluated fractions, 15 (30%) showed clinically meaningful improvements in sparing of highest-priority organ-at-risk (OAR) using the adaptive plans (P<sub>A</sub>), and 8 (16%) showed improved target coverage relative to the scheduled plan. Both MC-based secondary dose checks and log file-based machine QA were within institutional tolerance criteria, confirming the dosimetric accuracy and delivery fidelity of the workflow. A fully integrated, QA-embedded online adaptive proton therapy workflow using in-room CT-on-rails imaging was developed and validated in silico on a clinical proton beamline. The workflow demonstrated clinically acceptable treatment times and reliable dosimetric accuracy and provided measurable benefits in OAR sparing and target coverage for a substantial subset of fractions. These results support the readiness of this workflow for clinical use.